Your browser doesn't support javascript.
loading
TIGIT Marks Exhausted T Cells, Correlates with Disease Progression, and Serves as a Target for Immune Restoration in HIV and SIV Infection.
Chew, Glen M; Fujita, Tsuyoshi; Webb, Gabriela M; Burwitz, Benjamin J; Wu, Helen L; Reed, Jason S; Hammond, Katherine B; Clayton, Kiera L; Ishii, Naoto; Abdel-Mohsen, Mohamed; Liegler, Teri; Mitchell, Brooks I; Hecht, Frederick M; Ostrowski, Mario; Shikuma, Cecilia M; Hansen, Scott G; Maurer, Mark; Korman, Alan J; Deeks, Steven G; Sacha, Jonah B; Ndhlovu, Lishomwa C.
Afiliação
  • Chew GM; Hawaii Center for HIV/AIDS, Department of Tropical Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, United States of America.
  • Fujita T; Hawaii Center for HIV/AIDS, Department of Tropical Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, United States of America.
  • Webb GM; Department of Microbiology and Immunology, Tohoku University Graduate School of Medicine, Sendai, Japan.
  • Burwitz BJ; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, Oregon, United States of America.
  • Wu HL; Oregon National Primate Research Center, Oregon Health and Science University, Portland, Oregon, United States of America.
  • Reed JS; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, Oregon, United States of America.
  • Hammond KB; Oregon National Primate Research Center, Oregon Health and Science University, Portland, Oregon, United States of America.
  • Clayton KL; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, Oregon, United States of America.
  • Ishii N; Oregon National Primate Research Center, Oregon Health and Science University, Portland, Oregon, United States of America.
  • Abdel-Mohsen M; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, Oregon, United States of America.
  • Liegler T; Oregon National Primate Research Center, Oregon Health and Science University, Portland, Oregon, United States of America.
  • Mitchell BI; Vaccine and Gene Therapy Institute, Oregon Health and Science University, Portland, Oregon, United States of America.
  • Hecht FM; Oregon National Primate Research Center, Oregon Health and Science University, Portland, Oregon, United States of America.
  • Ostrowski M; Department of Immunology, University of Toronto, Toronto, Ontario, Canada.
  • Shikuma CM; Department of Microbiology and Immunology, Tohoku University Graduate School of Medicine, Sendai, Japan.
  • Hansen SG; Division of Experimental Medicine, Department of Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, California, United States of America.
  • Maurer M; Division of Experimental Medicine, Department of Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, California, United States of America.
  • Korman AJ; Hawaii Center for HIV/AIDS, Department of Tropical Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, United States of America.
  • Deeks SG; HIV/AIDS Division, Department of Medicine, San Francisco General Hospital, University of California, San Francisco, San Francisco, California, United States of America.
  • Sacha JB; Department of Immunology, University of Toronto, Toronto, Ontario, Canada.
  • Ndhlovu LC; Hawaii Center for HIV/AIDS, Department of Tropical Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, Hawaii, United States of America.
PLoS Pathog ; 12(1): e1005349, 2016 Jan.
Article em En | MEDLINE | ID: mdl-26741490
ABSTRACT
HIV infection induces phenotypic and functional changes to CD8+ T cells defined by the coordinated upregulation of a series of negative checkpoint receptors that eventually result in T cell exhaustion and failure to control viral replication. We report that effector CD8+ T cells during HIV infection in blood and SIV infection in lymphoid tissue exhibit higher levels of the negative checkpoint receptor TIGIT. Increased frequencies of TIGIT+ and TIGIT+ PD-1+ CD8+ T cells correlated with parameters of HIV and SIV disease progression. TIGIT remained elevated despite viral suppression in those with either pharmacological antiretroviral control or immunologically in elite controllers. HIV and SIV-specific CD8+ T cells were dysfunctional and expressed high levels of TIGIT and PD-1. Ex-vivo single or combinational antibody blockade of TIGIT and/or PD-L1 restored viral-specific CD8+ T cell effector responses. The frequency of TIGIT+ CD4+ T cells correlated with the CD4+ T cell total HIV DNA. These findings identify TIGIT as a novel marker of dysfunctional HIV-specific T cells and suggest TIGIT along with other checkpoint receptors may be novel curative HIV targets to reverse T cell exhaustion.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptores Imunológicos / Linfócitos T CD4-Positivos / Infecções por HIV / Linfócitos T CD8-Positivos Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: PLoS Pathog Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Receptores Imunológicos / Linfócitos T CD4-Positivos / Infecções por HIV / Linfócitos T CD8-Positivos Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Revista: PLoS Pathog Ano de publicação: 2016 Tipo de documento: Article País de afiliação: Estados Unidos